Imidazoline receptor agonist drugs for treatment of systemic hypertension and congestive heart failure.
The imidazoline receptors recently have been discovered to be involved in the central nervous system control of sympathetic outflow. A new class of centrally acting antihypertensive agents, the imidazoline receptor agonists (rilmenidine and moxonidine), have been developed to control blood pressure effectively without the adverse effects of sedation and mental depression that usually are associated with centrally acting antihypertensive agents. This new generation of centrally acting antihypertensive agents is highly selective for the imidazoline receptor but has a low affinity for alpha(2)-adrenergic receptors. The usefulness of these agents in the treatment of congestive heart failure has not been demonstrated.
Palkhiwala
S A
SA
Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY 10595, USA.
Yu
A
A
Frishman
W H
WH
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002545:Brain Ischemia / Q000517:prevention & control; D002986:Clinical Trials as Topic; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use; D054755:Imidazoline Receptors; D010080:Oxazoles / Q000627:therapeutic use; D011955:Receptors, Drug / Q000819:agonists*; D051437:Renal Insufficiency / Q000188:drug therapy; D000077769:Rilmenidine
D000959:Antihypertensive Agents; D007093:Imidazoles; D054755:Imidazoline Receptors; D010080:Oxazoles; D011955:Receptors, Drug; C043482:moxonidine; D000077769:Rilmenidine